The Pain Perspective in Scleroderma PDF Print E-mail
Monday, 18 July 2011 08:46
Systemic sclerosis (scleroderma) is a disease in which inflammatory and fibrotic changes result in overproduction and accumulation of collagen and other extracellular matrix proteins, resulting in intimal vascular damage, fibrosis, and occasionally organ dysfunction affecting the gastrointestinal, lung, heart, and renal systems.

There are two classifications of Scleroderma - limited cutaneous or CREST (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, and telangectasias) syndrome, where skin thickening occurs mainly in the distal extremities and facial/neck areas and internal organ involvement, if present, occurs later in the disease process; and diffuse cutaneous disease where there is a more rapid progression of skin thickening from distal to proximal and organ involvement can be severe and occur early in the disease. As noted by various authors, there is no “crystal ball” into which one can look to see the outcome of the disease, and involvement varies significantly from one person to the next.

The role of the nurse practitioner/physician assistant is integral in assessing the various components of disability and pain experienced by the scleroderma patient. We work closely with various disciplines, including occupational and physical therapists, who can add greatly to the everyday functioning of our patients who need braces, splints, adaptive equipment, and rehabilitation therapy to pursue cherished activities when claw deformities, skin tethering, and breathing difficulties or other organ involvement interferes with activities of daily living.

Pain takes many forms with our scleroderma patients. Arthralgias and muscle tenderness, difficulty with swallowing, constipation resulting in “rabbit pellet” stools, and air hunger or subjective feelings of shortness of breath can lead to depression and disability. Medications can ease symptoms and promote quality of life, and a complete review of systems, including functional assessment, should be an integral part of every clinic visit, with therapies geared toward promoting optimal health and decreasing disability.

How exactly do we assess disability in this complex and variably presenting disease? As Sultan et al have lamented, no one to date has adequately defined the concept of disability in scleroderma, particularly across cultural lines. Is it the functional component or the disability component that should lend weight to our formal assessments? Several measurement tools have been identified for use in clinical trials. The Hand Mobility in Scleroderma Test (HAMIS), the United Kingdom Scleroderma Functional Score, and the Rodnan skin scoring system have been used extensively.

Ultrasound is an emerging imaging technique that is readily available and noninvasive, allowing for the evaluation of dermal thickening and echogenicity. One tool that is validated and used extensively in the rheumatoid and osteoarthritis populations is the Health Assessment Questionnaire Disease Index (HAQ-DI), a measurement of disability evaluating eight domains of activity. A hybrid of the HAQ-DI, the Scleroderma Health Assessment Questionnaire (SHAQ), first used by Steen and Medsger, adds five scleroderma-specific visual analog scales to evaluate how Raynaud’s phenomenon, digital ulcerations, breathing, and intestinal problems as well as disease activity impact the individual patient. This tool has been evaluated for different construct validities, is fairly easy to use in the office as well as in clinical trials, and can be used to evaluate overall patient functioning, thus streamlining the patient visit.

The SHAQ also has utility in sculpting treatment. By allowing patients to assess their own pain and functional level, practitioners can then tweak therapies to decrease the overall symptom burden, thus allowing patients to have more normal routines. The chronicity of autoimmune disease should not be forgotten here. Pain takes many forms leading to loss of independence and self-image issues that can add to a sense of depression and even hopelessness. Exploring the issues of functional assessment from a sexual, mental, and physical dynamic is truly the “art” we all bring to patient care.

As a nurse practitioner working in rheumatology for 10 years, I couldn’t have stumbled into a more rewarding field. Being able to diagnose, apply effective treatments, and monitor disease progression all the while employing this model of patient-centered care and looking at the patient in their entirety, treating their various pain syndromes, and addressing psychosocial aspects of their day-to-day experiences has been a fulfilling calling.

Source: Williams, S. (2011), "Pain Perspective in Scleroderma", The Rheumatologist; original article can be viewed here.

 
More articles :

» Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges

Cristina Rigamonti, Dimitrios P. Bogdanos, Maria G.Mytilinaiou, Daniel S. Smyk, Eirini I. Rigopoulou, and Andrew K. BurroughsReceived 3 June 2011; Accepted 7 September 2011Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease...

» The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

Marta Baleva and Krasimir NikolovReceived 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in Scleroderma is...

» What's Your Scleroderma Action Plan?

Living with any serious disease or condition like Scleroderma, is without a doubt, difficult. It is not hard to understand either, that we often can lose sight of what is important, including our way. We may also fall into to a false sense of...

» Two Problems That People With Scleroderma Face: Malabsorption and Inflammation

According to , many doctors agree that starts with inflammation, and its progress depends on how much inflammation continues to occur in the body. That's one reason some doctors recommend that patients with any sort of inflammatory disease such as...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...

» Calcium Deposits Under the Skin

Numerous health effects or conditions are associated with calcinosis or calcium deposits under the skin. According to the , calcinosis is the medical term for calcium deposits that can form under the skin or in the muscles. Calcium deposits in these...